| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000007439 |
| Receipt No. | R000008699 |
| Official scientific title of the study | The safety, efficacy and the predictive factors of efficacy of beclomethasone dipropionate (BDP) for acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation |
| Date of disclosure of the study information | 2012/03/05 |
| Last modified on | 2019/01/18 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | The safety, efficacy and the predictive factors of efficacy of beclomethasone dipropionate (BDP) for acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation | |
| Title of the study (Brief title) | The safety, efficacy and the predictive factors of efficacy of BDP for acute GVHD | |
| Region |
|
|
| Condition | ||
| Condition | Hematologic disorders
gastrointestinal acute GVHD |
|
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the safety and efficacy of oral BDP for gastrointestinal acute GVHD and to identify factors of predicting efficacy |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | The complete response rate of gastrointestinal acute GVHD at day28 after starting treatment |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | BDP treatment for gastrointestinal acute GVHD. Both plain gelatin and enteric-coated gelatin capsule of hospital preparation are manufactured by filling 1mg BDP in the pharmaceutical department of our institution. Patients will receive one uncoated and one enteric- coated capsule orally four times a day. | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with biopsy-proven or clinically strongly suspected gastrointestinal acute GVHD and with symptoms (including nausea or vomiting without >=500ml of diarrhea/day) and with inadequate oral intake (<70% of daily caloric requirements) | |||
| Key exclusion criteria | 1. Patients requiring systemic steroid treatment for grade 2 acute GVHD of skin and/or liver
2. Patients who cannot intake oral BDP 3. Uncontrollable infection in the gastrointestinal tract 4. Pregnant or possibility pregnant woman 5. Inappropriate to participate in this study as judged by the physician in charge |
|||
| Target sample size | 26 | |||
| Research contact person | |
| Name of lead principal investigator | Masayuki Hino |
| Organization | Graduate School of Medicine, Osaka City University |
| Division name | Hematology |
| Address | 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan. 545-8585 |
| TEL | 06-6645-3881 |
| hinom@med.osaka-cu.ac.jp | |
| Public contact | |
| Name of contact person | Mitsutaka Nishimoto |
| Organization | Graduate School of Medicine, Osaka City University |
| Division name | Hematology |
| Address | 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan. 545-8585 |
| TEL | 06-6645-3881 |
| Homepage URL | |
| nishimo@med.osaka-cu.ac.jp | |
| Sponsor | |
| Institute | Hematology,Graduate School of Medicine, Osaka City University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008699 |